PRESS RELEASE: ASBESTOS DISEASE AWARENESS ORGANIZATION CALLS ASBESTOS TRUST FUND LEGISLATION "CORPORATE BAILOUT"
May 31, 2005 08:02

The Asbestos Disease Awareness Organization (ADAO), an organization dedicated to serving as the voice of asbestos victims, announced its extreme disappointment regarding the passage S. 852, the asbestos trust fund bill sponsored by Senator Arlen Specter. "We... (Read Article)

When the drug industry came under fire last summer for
failing to disclose poor results from studies of
antidepressants, major drug makers promised to provide
more information about their research on new medicines.
But nearly a year later, crucial facts about many
clinical trials remain hidden, scientists independent
of the companies say. Within the drug industry,
companies are sharply divided about how much
information to reveal, both about new studies and
completed studies for drugs already being sold. The
split is unusual in the industry, where companies
generally take similar stands on regulatory issues.
Eli Lilly and some other companies have posted
hundreds of trial results on the Web and pledged to
disclose all results for all drugs they sell. But
other drug makers, including Merck and Pfizer, release
less information and are reluctant to add more, citing competitive pressures. As a result, doctors and
patients lack critical information about important
drugs, academic researchers say, and the companies
can hide negative trial results by refusing to publish
studies, or by cherry-picking and highlighting the
most favorable data from studies they do publish.
*****
Alex Berenson, The New York Times, 05/31/2005